65 results
10-Q
2021 Q1
EX-10.2
KIN
Kindred Biosciences Inc
Quarterly report
11 May 21
4:11pm
10-K
2020 FY
EX-10.29
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.12
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.26
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
10-K
2020 FY
EX-10.30
KIN
Kindred Biosciences Inc
Annual report
16 Mar 21
4:06pm
8-K
EX-10.1
xb4zw7 54
5 Aug 20
Kindred Biosciences Announces Second Quarter 2020 Financial Results
4:09pm
8-K
EX-10.1
eqt0 lskp1
17 Jun 20
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.1
41cpbym8fzhuuztlkv
8 Apr 20
Entry into a Material Definitive Agreement
4:04pm
8-K
EX-10.1
ccl1aqkmno n3
16 Mar 20
Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction and Reports Fourth Quarter and Full Year 2019 Financial Results
4:08pm
8-K
EX-10.1
57jvy sjw6m49fv
2 Oct 19
Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners
4:18pm
8-K
EX-10.4
izmnh 1ku52b1liew
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.1
m36o81r uolodcigzw7p
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.3
9fjv nbg320zbq4928q
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.2
uwy igywpf19f5ch
29 May 18
Departure of Directors or Certain Officers
4:04pm
8-K
EX-10.1
eto27ua2il zcg
7 May 18
Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats
7:05am